Researchers are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition.
Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback